A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Enrolling by invitation · NCT05741242 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | cancer, neoplasm | Enrolling by invitation | Phase 1 / Phase 2 | 2026-09-29 | NCT05741242 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jaime Leandro Foundation for Therapeutic Cancer Vaccines | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anna Gattani MD PC | New York | United States | 1 |
| Asthra Health | Santa Monica | United States | 1 |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | United States | 26 |
| Precision NextGen Oncology & Research Center | Beverly Hills | United States | 6 |
| Quest Clinical Research | San Francisco | United States | 8 |
| St. Louis Cancer Care | Bridgeton | United States | 1 |